方法：采用前瞻性临床随机对照试验。将行白内障超声乳化吸除联合人工晶状体植入术的年龄相关性白内障患者随机分为两组，每组118眼。试验组：术前2d和术后4wk应用1g/L溴芬酸钠水合物滴眼液，联合术后2wk应用妥布霉素地塞米松滴眼液； 对照组：术后2wk应用妥布霉素地塞米松滴眼液。分别在术前2d内，术后1d、1、4、12wk测定黄斑中心亚区域平均厚度(CSMT)，并计算术后黄斑水肿发生率。

结果：术前、术后1d，1、12wk试验组与对照组CSMT比较，差异均无统计学意义(P>0.05)； 术后4wk试验组CSMT为251.57±6.814μm，低于对照组的262.41±7.295μm，差异有统计学意义(P<0.05)； 术后1d，1、4、12wk试验组黄斑水肿发生率分别为0、0、0.9%、0.9%，对照组分别为0、0.9%、8.5%、1.7%，两组黄斑水肿发生率比较，仅术后4wk差异有统计学意义(P<0.05)。

结论：白内障超声乳化术前和术后应用1g/L溴芬酸钠水合物滴眼液，能有效预防术后黄斑中心亚区域增厚，减少黄斑水肿发生率。

METHODS:In this prospective, randomized, controlled clinical trial, the cases with age related cataract after phacoemulsification combined with intraocular lens implantation were randomly divided into two groups, each group of 118 eyes. The cases in experimental group received the treatment of 1g/L bromfenac sodium hydrate ophthalmic solution for 2d preoperatively and 4wk postoperatively, combined with tobramycin dexamethasone eye drops for 2wk postoperatively. The cases in control group received the treatment of tobramycin dexamethasone eye drops for 2wk postoperatively. Central subfield mean thickness(CSMT)was measured within 2d before surgery as well as on 1d, 1, 4, 12wk after surgery and the incidence of macular edema was calculated after surgery.

RESULTS:There was no significant difference in CSMT between two groups before surgery and on 1d, 1, 12wk after surgery(P>0.05). CSMT was significantly lower in experimental group(251.57±6.814μm)than in control group(262.41±7.295μm)on 4wk after surgery(P<0.05). The incidence of macular edema in experimental group on 1d, 1, 4, 12wk after surgery were 0, 0, 0.9% and 0.9%, respectively, while in control group were 0, 0.9%, 8.5% and 1.7%, respectively. There was significant difference in the incidence of macular edema between two groups only on 4wk after surgery(P<0.05).

CONCLUSION:The thickening of central subfield can be effectively prevented and the incidence of macular edema can be reduced with 1g/L bromfenac sodium hydrate ophthalmic solution performed before and after phacoemulsification.